A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MK-3475-522/KEYNOTE-522
- Sponsors Merck Sharp & Dohme
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 16 Mar 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.